Enabling Novel Vaccine Discovery
Designed to increase the efficiency and quality of vaccine discovery, Genedata's purpose-built, end-to-end enterprise platform supports the full discovery process and enables faster testing, simplified production, and reduced costs.
Vaccines
In addition to classical vaccine R&D approaches, Genedata Biologics supports novel vaccine technologies such as synthetic self-amplifying mRNA, which accelerates vaccine development by utilizing synthetic and cell-free processes. The platform paves the way for the discovery of novel vaccines, even for antigens that are extremely difficult to produce and formulate.
Genedata helped us get to the next level of streamlining our data management workflow
Ciaran Scallan, Ph.D.
Vice President, Vaccine Technology & Molecular Biology
Given their track-record of success, Genedata’s platform was the clear choice to support and integrate our full cell therapy discovery and development efforts.
Marc Van Dijk, Ph.D.
Chief Technology Officer
We work at a fast pace and push the boundaries of science. Genedata provided a platform that could be rolled out with minimal customization required
Ciaran Scallan, Ph.D
Vice President, Vaccine Technology & Molecular Biology
